MediWound Ltd. (MDWD)

Market Cap	82.47M
Revenue (ttm)	24.97M
Net Income (ttm)	-12.43M
Shares Out	9.21M
EPS (ttm)	-1.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,056
Open	9.00
Previous Close	9.10
Day's Range	8.90 - 9.11
52-Week Range	7.10 - 14.58
Beta	1.05
Analysts	Strong Buy
Price Target	28.00 (+214.61%)
Earnings Date	Nov 21, 2023

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other ha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 83
• Stock Exchange: NASDAQ
• Ticker Symbol: MDWD

Financial Performance

In 2022, MediWound's revenue was $26.50 million, an increase of 11.50% compared to the previous year's $23.76 million. Losses were -$19.60 million, 44.6% more than in 2021.

Analyst Forecast

According to 4 analysts, the average rating for MDWD stock is "Strong Buy." The 12-month stock price forecast is $28.0, which is an increase of 214.61% from the latest price.

Price Target

$28.0

(214.61% upside)

Analyst Consensus: Strong Buy